Unilever Outlines Strategy Behind $68 Billion GSK Consumer Health Care Bid

The company has so far had three bids rejected as it aims to extend its offer in health, beauty and hygiene

Inspiration meets innovation at Brandweek, the ultimate marketing experience. Join industry luminaries, rising talent and strategic experts in Phoenix, Arizona this September 23–26 to assess challenges, develop solutions and create new pathways for growth. Register early to save.

Unilever has outlined why it has tabled three bids, with the latest at around $68 billion, for the Consumer Healthcare division of GlaxoSmithKline (GSK). Following an “extensive” review, the British owner of Ben & Jerry’s, PG Tips, Dove and Lipton Tea has decided that its strategic direction should be to “materially expand” its health, beauty and hygiene offer.

The management and board of Unilever released a statement following press reports of the bid for the health care giant’s division, which GSK claimed “fundamentally undervalues” the business.

“These

AW+

WORK SMARTER - LEARN, GROW AND BE INSPIRED.

Spring Special

Save 30% Off an ADWEEK Subscription Today!

View Your Options

Already a member? Sign in